| Literature DB >> 24698709 |
Ana Lucia L Lima1, Priscila R Oliveira2, Vladimir C Carvalho1, Sergio Cimerman3, Eduardo Savio4.
Abstract
With the advances in surgical treatment, antibiotic therapy and the current resources for accurate diagnosis and differentiated approaches to each type of osteomyelitis, better results are being obtained in the treatment of this disease. After a careful literature review carried out by a multiprofessional team, some conclusions were made in order to guide medical approach to different types of osteomyelitis, aiming to obtain better clinical outcomes and reducing the social costs of this disease. Acute and chronic osteomyelitis are discussed, with presentation of the general epidemiological concepts and the commonly used classification systems. The main guidelines for the clinical, laboratory and imaging diagnosis of infections are discussed, as well as the guidelines for surgical and antimicrobial treatments, and the role of hyperbaric oxygen as adjuvant therapy.Entities:
Keywords: Bone and joint infection; Infectious diseases; Osteomyelitis; Soft tissue infection
Mesh:
Substances:
Year: 2014 PMID: 24698709 PMCID: PMC9428226 DOI: 10.1016/j.bjid.2013.12.005
Source DB: PubMed Journal: Braz J Infect Dis ISSN: 1413-8670 Impact factor: 3.257
Waldvogel classification of osteomyelitis.
| Characteristics | |
|---|---|
| Hematogenous | Secondary to bacterial transport through the blood. Majority of infections in children |
| Contiguous | Bacterial inoculation from an adjacent focus. E.g.: Post-traumatic Osteomyelitis, infections related to prosthetic devices |
| Associated with vascular insufficiency | Infections affecting the feet in patients with diabetes, hanseniasis or peripheral vascular insufficiency |
| Acute | Initial episodes of osteomyelitis. Edema, formation of pus, vascular congestion, thrombosis of the small vessels |
| Chronic | Recurrence of acute cases. Large areas of ischemia, necrosis and bone sequestra |
Cierny and Mader classification of osteomyelitis.
| Characteristics | |
|---|---|
| 1 – Medullary | Infection restricted to the bone marrow |
| 2 – Superficial | Infection restricted to cortical bone |
| 3 – Localized | Infection with clearly defined edges and bone stability preserved |
| 4 – Diffuse | Infection spread to the entire bone circumference, with instability before or after debridement |
| A – Host healthy | Patient without comorbidities |
| Bl – Local compromise | Smoking, chronic lymphedema, venous stasis, arthritis, large scars, fibrosis by radiotherapy |
| Bs – Systemic compromise | |
| C – Poor clinical conditions | Surgical treatment will have higher risk than the osteomyelitis itself |
Bone penetration of antibiotics.
| Antibiotic | Time interval since last dose (h) | Bone/serum concentration ratio |
|---|---|---|
| Amoxycillin | 2 | 0.17–0.31 |
| Amoxycillin + clavulanate | 0.5–6 | 0.01–0.09 |
| Ampicillin | 0.25–4 | 0.11–0.71 |
| Sulbactam | 0.25–4 | 0.11–0.71 |
| Piperacillin | 1 | 0.18–0.23 |
| Tazobactam | 1 | 0.22–0.26 |
| Oxacillin | 1 | 0.11 |
| Ertapenem | 1.6–23.8 | 0.13–0.19 |
| Ceftriaxone | 0.2–8 | 0.07–0.17 |
| Cefazolin | 0.9 | 0.17 |
| Cefepime | 1–2 | 0.46–0.76 |
| Ceftazidime | 2 | 0.54 |
| Erythromycin | 0.25–2 | 0.18–0.28 |
| Azithromycin | 0.5–6.5 days | 2.5–6.3 |
| Clindamycin | 1–2 | 0.21–0.45 |
| Rifampin | 2–14 | 0.08–0.56 |
| Rifampin (osteomyelitis) | 3.5–4.5 | 0.57 |
| Tigecycline | 4–24 | 0.35–1.95 |
| Levofloxacin | 0.7–2 | 0.36–1.0 |
| Ciprofloxacin | 0.5–13 | 0.27–1.2 |
| Ciprofloxacin (osteomyelitis) | 2–4.5 | 0.42 |
| Vancomycin | 0.7–6 | 0.05–0.67 |
| Vancomycin (osteomyelitis) | 1–7 | 0.27 |
| Linezolid | 0.5–1.5 | 0.4–0.51 |
| Linezolid (osteomyelitis) | 0.9 | 0.23 |
| Daptomycin | 2 | 1.08 |
| Teicoplanin | 4–16 | 0.5–0.64 |
Suggested empirical initial antimicrobial regimens for osteomyelitis.
| Clinical situation | Initial antimicrobial | Possible oral regimens | |
|---|---|---|---|
| Community associated | Acute (child < 4 months or NB) | Oxacillin, cefazolin or clindamycin | Starting oral treatment in this situation is not recommended. After obtaining the culture results, the regimen is adjusted |
| Acute (child > 4 months or NB) | Oxacillin or cefazolin | Starting oral treatment in this situation is not recommended. After obtaining the culture results, the regimen is adjusted | |
| Acute adults | Oxacillin or cefazolin | Starting oral treatment in this situation is not recommended. After obtaining the culture results, the regimen is adjusted | |
| Healthcare associated | Child and adults (for example, infection after fracture fixation) | Glycopeptide + ceftazidime, cefepime, iperacillin/tazobactan or carbapenem agents | Starting oral treatment in this situation is not recommended. After obtaining the culture results, the regimen is adjusted |
| Hemoglobinopathy | Ceftriaxone or fluoroquinolone | Fluoroquinolone | |
Considering local prevalence of CA-MRSA.
Considering local patterns of bacterial susceptibility.